Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate. It is postulated that IL-2 administered after ASCT may eliminate minimal residual disease and thereby reduce relapses. A phase I/II study was performed to identify a regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, N, Benyunes, MC, Thompson, JA, York, A, Petersdorf, S, Press, O, Lindgren, C, Chauncey, T, Buckner, CD, Bensinger, WI, Appelbaum, FR, Fefer, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 1997
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092324/
https://www.ncbi.nlm.nih.gov/pubmed/9052908
http://dx.doi.org/10.1038/sj.bmt.1700687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092324/
https://www.ncbi.nlm.nih.gov/pubmed/9052908
http://dx.doi.org/10.1038/sj.bmt.1700687

Ejemplares similares